Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/cen.13102 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gut microbiota derived metabolite trimethylamine N-oxide influences prostate cancer progression via the p38/HMOX1 pathway.
Front Pharmacol
January 2025
Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Background: Prostate cancer was the fourth most diagnosed cancer worldwide in 2022. Radical treatments and androgen deprivation therapy benefit newly diagnosed patients but impact quality of life, often leading to castration-resistant prostate cancer. Short-term dietary changes significantly affect the gut microbiota, which differs markedly between prostate cancer patients and healthy individuals, impacting both cancer progression and treatment response.
View Article and Find Full Text PDFHighly hypofractionated biaxially rotational dynamic radiation therapy (BROAD-RT) for high-risk prostate cancer.
Cancer Sci
January 2025
Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
To report clinical outcomes following highly hypofractionated biaxially rotational dynamic radiation therapy (BROAD-RT), a unique radiation therapy method that facilitates non-coplanar volumetric-modulated arc therapy (VMAT) without the need to rotate the couch or reposition the patient, for high-risk prostate cancer (PCa) with simultaneous integrated boost (SIB) for intra-prostatic dominant lesions (IPDLs), we performed a single-center prospective pilot study. In this study, patients with high-risk PCa according to the D'Amico classification or those with cT3aN0M0 PCa were eligible. VMAT was performed using BROAD-RT, and a dose of 54 Gy in 15 fractions was prescribed for the prostate in combination with SIB for IPDLs at a dose of 57 Gy in 15 fractions.
View Article and Find Full Text PDFEvaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer.
Prostate Cancer Prostatic Dis
January 2025
South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia.
Article Synopsis
- The study analyzes how clinical risk stratification can be used to assess the advantages of long-term androgen deprivation therapy (ltADT) compared to short-term therapy (stADT) in high-risk localized prostate cancer patients.
- Results indicate that patients with very-high risk features have greater improvements in survival outcomes when treated with ltADT, although the variation in treatment effects across different risk groups is not statistically significant.
- The findings suggest the need for further clinical trials to refine risk stratification methods and better identify which high-risk localized prostate cancer patients could benefit more from longer therapy.
Background: Prostate cancer therapy with surgical or chemical castration with gonadotropin-releasing hormone (GnRH) agonists has been linked to elevated follicle-stimulating hormone (FSH) levels, which may contribute to secondary health disorders, including atherosclerosis and diabetes. Although recent findings suggest a role for FSH beyond the reproductive system, its metabolic impact remains unclear and difficult to disentangle from that of androgens. In this study, we examined the metabolic changes induced by FSH and distinguished them from those caused by testosterone.
View Article and Find Full Text PDFPatterns of Recurrence Following Radiation and ADT for Pathologic Lymph Node-Positive Prostate Cancer: A Multi-institutional Study.
Pract Radiat Oncol
December 2024
Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, Ohio.
Purpose: We evaluate prognostic factors and patterns of recurrence in patients who received RT ± androgen deprivation therapy (ADT) for pathologic node-positive (pN1) prostate cancer (PCa) in a multi-institutional cohort.
Methods And Materials: Data from patients with pN1 PCa and received RT with short-term (ST, ≤6 mo) or long-term (LT, >6 mo) ADT were obtained from 4 academic institutions. Biochemical progression-free survival (bPFS) and distant metastasis-free survival (DMFS) were evaluated.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!